Internal Medicine, Infectious Disease · Camden, SC
NPI
1740201680
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
4
Medicare group memberships
Hospitals
3
Hospital affiliations
1315 Roberts St
Camden, SC, 29020
Phone (803) 427-3162
Groups this clinician bills Medicare through
Medicare paid, 2024
$42K
645 services
Medicare patients, 2024
115
Average age 77
Drug cost, 2024
$8.4M
3,048 prescriptions
Company payments, 2025
$150
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Akinwale O Olatosi was code 99232 (hospital e&m - subsequent), 419 times for 86 patients. In total Akinwale O Olatosi billed 645 services in 13 codes, and Medicare paid $42K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-06-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 419 | 86 | $58.61 | $25K |
| 99222 Hospital E&M - Initial | Facility | 103 | 93 | $94.46 | $9,730 |
| 99213 Office E&M - Established | Office | 70 | 43 | $62.96 | $4,407 |
| 99231 Hospital E&M - Subsequent | Facility | 18 | 12 | $36.77 | $662 |
By year: 2022 $67K for 1,029 services; 2023 $52K for 832 services; 2024 $42K for 645 services.
Medicare prescription drug claims, 2024
In 2024, the drug Akinwale O Olatosi prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 1,415 prescriptions and refills. In total Akinwale O Olatosi wrote 3,048 Medicare prescriptions that cost $8.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 1,415 | 1,415 | 141 | $5.4M |
| Tivicay Dolutegravir Sodium | 403 | 403 | 39 | $976K |
| Descovy Emtricitabine/Tenofov Alafenam | 340 | 340 | 32 | $718K |
| Isentress Raltegravir Potassium | 140 | 140 | 13 | $268K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 94 | 94 | Under 11 | $330K |
| Darunavir Generic | 69 | 69 | Under 11 | $27K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 63 | 63 | Under 11 | $337 |
| Abacavir Abacavir Sulfate | 58 | 64 | Under 11 | $5,397 |
| Ritonavir Generic | 53 | 61 | Under 11 | $4,385 |
| Lamivudine Generic | 31 | 33 | Under 11 | $1,929 |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 27 | 27 | Under 11 | $123K |
| Lamivudine Hbv Lamivudine | 26 | 26 | Under 11 | $2,919 |
| Etravirine Generic | 23 | 23 | Under 11 | $25K |
| Prezcobix Darunavir/Cobicistat | 20 | 20 | Under 11 | $45K |
| Cefepime Hcl Generic | 16 | 16 | Under 11 | $735 |
Brand drugs: 2,548 claims; generic drugs: 500 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Akinwale O Olatosi $150 ($150 in general payments such as food, travel and fees) from 5 companies. The largest payer was ViiV Healthcare Company with $47.54.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.